Incyte Corp reports results for the quarter ended March 31 - Earnings Summary

• Incyte Corp INCY.OQ reported quarterly adjusted earnings of $1.16​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of 64 cents. The mean expectation of twenty two analysts for the quarter was for earnings of $1.02 per share. Wall Street expected results to range from 76 cents to $1.35 per share.

• Revenue rose 19.5% to $1.05 billion from a year ago; analysts expected $993.12 million.

• Incyte Corp's reported EPS for the quarter was 80 cents​.

• The company reported quarterly net income of $158.2 million.

• Incyte Corp shares had fallen by 1.7% this quarter and lost 13.8% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 7.1% in the last three months.​

• In the last 30 days, seven analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 16 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Incyte Corp is $74.00

This summary was machine generated from LSEG data April 29 at 12:53 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)